WuXi Bo Rui Biotechnology
Changping
About WuXi Bo Rui Biotechnology
WuXi Bo Rui Biotechnology develops a radioactive molecular imaging and nuclear drug transformation platform for the precise diagnosis and treatment of tumors. WuXi Bo Rui Biotechnology focuses on the transformation and development of new radionuclide drugs, covering multiple fields of small molecules, peptides, and antibodies, for the diagnosis and treatment of tumors, using their professional platform for targeted precursor design, screening, and radionuclide labeling. While increasing the efficiency of research and development, it also fully utilizes the benefits of accurate nuclear medicine diagnosis and treatment
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $42.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2022)
- Website: boomray.com
- Phone: +86-10-60769188
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/wuxi-bo-rui-biotechnology-129899 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.